164 related articles for article (PubMed ID: 11426069)
1. Cerebrospinal fluid response to structured treatment interruption after virological failure.
Price RW; Paxinos EE; Grant RM; Drews B; Nilsson A; Hoh R; Hellmann NS; Petropoulos CJ; Deeks SG
AIDS; 2001 Jul; 15(10):1251-9. PubMed ID: 11426069
[TBL] [Abstract][Full Text] [Related]
2. Effect of genotypic resistance on the virological response to highly active antiretroviral therapy in cerebrospinal fluid.
Cinque P; Presi S; Bestetti A; Pierotti C; Racca S; Boeri E; Morelli P; Carrera P; Ferrari M; Lazzarin A
AIDS Res Hum Retroviruses; 2001 Mar; 17(5):377-83. PubMed ID: 11282006
[TBL] [Abstract][Full Text] [Related]
3. Treatment benefit on cerebrospinal fluid HIV-1 levels in the setting of systemic virological suppression and failure.
Spudich S; Lollo N; Liegler T; Deeks SG; Price RW
J Infect Dis; 2006 Dec; 194(12):1686-96. PubMed ID: 17109340
[TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment.
Spudich SS; Nilsson AC; Lollo ND; Liegler TJ; Petropoulos CJ; Deeks SG; Paxinos EE; Price RW
BMC Infect Dis; 2005 Nov; 5():98. PubMed ID: 16266436
[TBL] [Abstract][Full Text] [Related]
5. Virological and pharmacological factors associated with virological response to salvage therapy after an 8-week of treatment interruption in a context of very advanced HIV disease (GigHAART ANRS 097).
Delaugerre C; Peytavin G; Dominguez S; Marcelin AG; Duvivier C; Gourlain K; Amellal B; Legrand M; Raffi F; Costagliola D; Katlama C; Calvez V
J Med Virol; 2005 Nov; 77(3):345-50. PubMed ID: 16173015
[TBL] [Abstract][Full Text] [Related]
6. Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression.
Ruiz L; Martinez-Picado J; Romeu J; Paredes R; Zayat MK; Marfil S; Negredo E; Sirera G; Tural C; Clotet B
AIDS; 2000 Mar; 14(4):397-403. PubMed ID: 10770542
[TBL] [Abstract][Full Text] [Related]
7. Cerebrospinal fluid and plasma HIV-1 RNA levels and lopinavir concentrations following lopinavir/ritonavir regimen.
Yilmaz A; Ståhle L; Hagberg L; Svennerholm B; Fuchs D; Gisslén M
Scand J Infect Dis; 2004; 36(11-12):823-8. PubMed ID: 15764168
[TBL] [Abstract][Full Text] [Related]
8. [Clinical and virological correlation between the cerebrospinal fluid and blood of HIV-infected children].
Sáez-Llorens X; Castrejón de Wong MC; Castaño E; de Suman O; Báez de Ulloa C; Redondo W; Espino M
Rev Med Panama; 2001; 26():13-8. PubMed ID: 16161718
[TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal fluid HIV-1 RNA levels in asymptomatic patients with early stage chronic HIV-1 infection: support for the hypothesis of local virus replication.
García F; Niebla G; Romeu J; Vidal C; Plana M; Ortega M; Ruiz L; Gallart T; Clotet B; Miró JM; Pumarola T; Gatell JM
AIDS; 1999 Aug; 13(12):1491-6. PubMed ID: 10465072
[TBL] [Abstract][Full Text] [Related]
10. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy.
Canestri A; Lescure FX; Jaureguiberry S; Moulignier A; Amiel C; Marcelin AG; Peytavin G; Tubiana R; Pialoux G; Katlama C
Clin Infect Dis; 2010 Mar; 50(5):773-8. PubMed ID: 20100092
[TBL] [Abstract][Full Text] [Related]
11. HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy.
Hermankova M; Ray SC; Ruff C; Powell-Davis M; Ingersoll R; D'Aquila RT; Quinn TC; Siliciano JD; Siliciano RF; Persaud D
JAMA; 2001 Jul; 286(2):196-207. PubMed ID: 11448283
[TBL] [Abstract][Full Text] [Related]
12. No benefit of a structured treatment interruption based on genotypic resistance in heavily pretreated HIV-infected patients.
Ghosn J; Wirden M; Ktorza N; Peytavin G; Aït-Mohand H; Schneider L; Dominguez S; Bricaire F; Calvez V; Costagliola D; Katlama C
AIDS; 2005 Oct; 19(15):1643-7. PubMed ID: 16184034
[TBL] [Abstract][Full Text] [Related]
13. Discordant CSF/plasma HIV-1 RNA in patients with unexplained low-level viraemia.
Nightingale S; Geretti AM; Beloukas A; Fisher M; Winston A; Else L; Nelson M; Taylor S; Ustianowski A; Ainsworth J; Gilson R; Haddow L; Ong E; Watson V; Leen C; Minton J; Post F; Pirmohamed M; Solomon T; Khoo S
J Neurovirol; 2016 Dec; 22(6):852-860. PubMed ID: 27194435
[TBL] [Abstract][Full Text] [Related]
14. Selection of drug-resistant HIV-1 mutants in response to repeated structured treatment interruptions.
Martinez-Picado J; Morales-Lopetegi K; Wrin T; Prado JG; Frost SD; Petropoulos CJ; Clotet B; Ruiz L
AIDS; 2002 Apr; 16(6):895-9. PubMed ID: 11919491
[TBL] [Abstract][Full Text] [Related]
15. Suppression of cerebrospinal fluid HIV burden in antiretroviral naive patients on a potent four-drug antiretroviral regimen.
Polis MA; Suzman DL; Yoder CP; Shen JM; Mican JM; Dewar RL; Metcalf JA; Falloon J; Davey RT; Kovacs JA; Feinberg MB; Masur H; Piscitelli SC
AIDS; 2003 May; 17(8):1167-72. PubMed ID: 12819518
[TBL] [Abstract][Full Text] [Related]
16. Factors influencing virological response to antiretroviral drugs in cerebrospinal fluid of advanced HIV-1-infected patients.
Antinori A; Giancola ML; Grisetti S; Soldani F; Alba L; Liuzzi G; Amendola A; Capobianchi M; Tozzi V; Perno CF
AIDS; 2002 Sep; 16(14):1867-76. PubMed ID: 12351946
[TBL] [Abstract][Full Text] [Related]
17. HIV infection of the central nervous system is characterized by rapid turnover of viral RNA in cerebrospinal fluid.
Eggers CC; van Lunzen J; Buhk T; Stellbrink HJ
J Acquir Immune Defic Syndr Hum Retrovirol; 1999 Mar; 20(3):259-64. PubMed ID: 10077174
[TBL] [Abstract][Full Text] [Related]
18. Evidence for independent development of resistance to HIV-1 reverse transcriptase inhibitors in the cerebrospinal fluid.
Cunningham PH; Smith DG; Satchell C; Cooper DA; Brew B
AIDS; 2000 Sep; 14(13):1949-54. PubMed ID: 10997399
[TBL] [Abstract][Full Text] [Related]
19. Delayed central nervous system virus suppression during highly active antiretroviral therapy is associated with HIV encephalopathy, but not with viral drug resistance or poor central nervous system drug penetration.
Eggers C; Hertogs K; Stürenburg HJ; van Lunzen J; Stellbrink HJ
AIDS; 2003 Sep; 17(13):1897-906. PubMed ID: 12960822
[TBL] [Abstract][Full Text] [Related]
20. Evidence of a source of HIV type 1 within the central nervous system by ultraintensive sampling of cerebrospinal fluid and plasma.
Haas DW; Clough LA; Johnson BW; Harris VL; Spearman P; Wilkinson GR; Fletcher CV; Fiscus S; Raffanti S; Donlon R; McKinsey J; Nicotera J; Schmidt D; Shoup RE; Kates RE; Lloyd RM; Larder B
AIDS Res Hum Retroviruses; 2000 Oct; 16(15):1491-502. PubMed ID: 11054262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
